<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040256</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0290</org_study_id>
    <nct_id>NCT05040256</nct_id>
  </id_info>
  <brief_title>Neurologic and Immunologic Characteristics of CTLA-4 and LRBA Hereditary Deficiency</brief_title>
  <official_title>Neurologic and Immunologic Characteristics of CTLA-4 and LRBA Hereditary Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CTLA4 and LRBA deficiencies are rare genetic disorders, recently described, and associated&#xD;
      with multiple clinical features. It ranges from recurrent infections, auto-immunity, and&#xD;
      organ infiltration with lymphocytes. Neurologic syndroms are described in up to 30% of&#xD;
      patients, yet they are poorly defined to date. Early recognition of a specific pattern can be&#xD;
      important, given that there is a targeted therapy in this situation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Neurologic impairment</measure>
    <time_frame>1 day</time_frame>
    <description>Neurologic signs and symptoms (headaches, seizures…), cerebral MRI features, lumbar puncture, histopathology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of reccurent infections</measure>
    <time_frame>1 day</time_frame>
    <description>Presence of reccurent infections and type, granulomatous disease, cancer predisposition, immunologic biological tests, type of treatments and effectiveness</description>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>CTLA4 Haploinsufficiency</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients listed with CTLA4 or LRBA deficiency in the register of the national reference&#xD;
        center for primary immunodeficiencies.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Patients diagnosed with CTLA4 or LRBA mutation&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Age &lt; 12 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Ayrignac, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Schindler MK, Pittaluga S, Enose-Akahata Y, Su HC, Rao VK, Rump A, Jacobson S, Cortese I, Reich DS, Uzel G. Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder. J Clin Invest. 2020 Oct 1;130(10):5551-5561. doi: 10.1172/JCI135947.</citation>
    <PMID>32955488</PMID>
  </results_reference>
  <results_reference>
    <citation>Ayrignac X, Goulabchand R, Jeziorski E, Rullier P, Carra-Dallière C, Lozano C, Portales P, Vincent T, Viallard JF, Menjot de Champfleur N, Rieux-Laucat F, Besnard C, Koenig M, Guissart C, Labauge P, Guilpain P. Two neurologic facets of CTLA4-related haploinsufficiency. Neurol Neuroimmunol Neuroinflamm. 2020 Jun 4;7(4). pii: e751. doi: 10.1212/NXI.0000000000000751. Print 2020 Jul.</citation>
    <PMID>32499327</PMID>
  </results_reference>
  <results_reference>
    <citation>Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schäffer AA, Grüning BA, Unger S, Frede N, Baumann U, Witte T, Schmidt RE, Dueckers G, Niehues T, Seneviratne S, Kanariou M, Speckmann C, Ehl S, Rensing-Ehl A, Warnatz K, Rakhmanov M, Thimme R, Hasselblatt P, Emmerich F, Cathomen T, Backofen R, Fisch P, Seidl M, May A, Schmitt-Graeff A, Ikemizu S, Salzer U, Franke A, Sakaguchi S, Walker LSK, Sansom DM, Grimbacher B. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014 Dec;20(12):1410-1416. doi: 10.1038/nm.3746. Epub 2014 Oct 20.</citation>
    <PMID>25329329</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LRBA deficiency</keyword>
  <keyword>Primary immunodeficiency</keyword>
  <keyword>Neuroinflammation</keyword>
  <keyword>Genetic diseases</keyword>
  <keyword>Autoimmune diseases</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

